Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms

Next Previous
Trial Profile

Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Urinary tract infections
  • Focus Adverse reactions

    • Most Recent Events

    • 04 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 26 Dec 2017 Planned initiation date changed from 15 Dec 2017 to 2 Dec 2017.
    • 13 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top